Casma Therapeutics, a Cambridge, MA-based biotechnology company, raised $46.0M in Series C funding.
The round was led by Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Euclidean Capital, Mirae Asset, and Ono Venture Investment, with participation from Eventide Asset Management, Schroders Capital, The Column Group, and Third Rock Ventures.
Dr. Hiromichi Kimura, Investment Director of Astellas Ventures, has joined the board of directors.
The company intends to use the funds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies.
Led by CEO Keith Dionne, Casma Therapeutics is developing cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. By selectively degrading disease targets by autophagy, the company expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.
FinSMEs
15/11/2022